Document is current
Any future updates will be listed below
-
Authors
De Moura, Alexandre https://orcid.org/0000-0002-5888-6399
Gleizes, Orane
Cabel, Luc
Bethune-Volters, Anne
Bellesoeur, Audrey
Bello-Roufai, Diana
Cottu, Paul
Sebbag, Clara
Loirat, Delphine
Geiss, Romain
Pierga, Jean-Yves
Escalup, Laurence
Bidard, François Clément
Genevée, Thomas
- License Information
-
More Information
Article History
Received: 25 March 2025
Accepted: 16 October 2025
First Online: 7 November 2025
Declarations
:
: D Bello-Roufai reported consulting fees from AstraZeneca, MSD and EISAI; support for attending meetings from Daiichi-Sankyo. D Loirat reported consulting fees from AstraZeneca, Daiichi-Sankyo, Roche and Pfizer; support for attending meetings from AstraZeneca, Daiichi-Sankyo and Roche. JY Pierga reported consulting fees from AstraZeneca, Daiichi-Sankyo, Novartis, Lilly, Roche, MSD and Gilead; support for attending meetings from AstraZeneca, Novartis, Gilead and Daiichi-Sankyo. FC Bidard reported consulting fees from AstraZeneca, Daiichi-Sankyo and Roche; research grants from Pfizer and AstraZeneca; support for attending meetings from AstraZeneca and Daiichi-Sankyo. Other authors declared no competing interests with this research.
